Bicara Therapeutics logo

Bicara Therapeutics

BCAX | NASDAQ
Chart Builder DCF Calculator
$9.75
-$0.27 (-2.69%)
At close: Nov 16, 2026, 4:00 PM ET
$9.75
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-2.69%

Rating

Updated: Nov 16, 2026
24.1
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #950/1021 (Top 93%)

Key Statistics

Market Data

Market Cap $647.28M
1D Range
9.55 10.17
52W Range
7.93 30.40

Valuation (TTM)

PE -2.81
PB 1.58
EV/EBITDA -0.94

Valuation (NTM)

Forward PE N/A
Forward PEG -0.06
Price Target $31.00
Loading financial charts...

Profile

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, du...

Sector Healthcare
Industry Biotechnology
Employees 103
IPO Date Sep 13, 2024
Fiscal Year January - December

Latest News

Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds

3 months ago · seekingalpha.com

Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results

3 months ago · benzinga.com

Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript

3 months ago · seekingalpha.com

Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript
Bicara Therapeutics Q2 Earnings Call Highlights

3 months ago · marketbeat.com

Bicara Therapeutics Q2 Earnings Call Highlights
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET

3 months ago · globenewswire.com

Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

4 months ago · globenewswire.com

Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript

6 months ago · seekingalpha.com

Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer

6 months ago · marketbeat.com

Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

6 months ago · globenewswire.com

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

6 months ago · marketbeat.com

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$31.00
Upside
+217.95%
Buy (6)
Hold (2)
Sell (1)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.